2-异丙基氧杂环丁烷 | 15045-60-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧杂环丁烷
• 中文名称: 2-异丙基氧杂环丁烷
• 英文名称: 2-isopropyloxetane
• 英文别名: 2-isopropyl-oxetane；2-Isopropyl-oxetan；2-i-Propyloxetan；2-propan-2-yloxetane
• CAS: 15045-60-0
• 化学式: C₆H₁₂O
• 分子量: 100.161
• InChiKey: RIELPFLYWOXARA-UHFFFAOYSA-N

物化性质

• 沸点：
  99.6±8.0 °C(Predicted)
• 密度：
  0.877±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2932999099

反应信息

• 作为产物：
  描述：

  2-甲基戊烷 在 氧气 作用下， 351.84 ℃ 、106.0 kPa 条件下， 生成 聚合甲醛 、 溶剂黄146 、 乙烯 、 乙醛 、 环氧乙烷 、 乙炔 、 甲醇 、 异丁烯 、 乙烷 、 三聚丙烯 、 丙酮 、 methyloxirane 、 丙炔 、 1,3-丁二烯 、 丙二烯 、 2,2-dimethyltetrahydrofuran 、 2,4-Dimethyltetrahydrofuran 、 3-Propyl-oxetan 、 3-乙基-2,2-二甲基环氧乙烷 、 2,2,4-三甲基氧杂环丁烷 、 2-异丙基氧杂环丁烷 、 methane
  参考文献：
  名称：

  Experimental Investigation of the Low Temperature Oxidation of the Five Isomers of Hexane

  摘要：

  The low-temperature oxidation of the five hexane isomers (n-hexane, 2-methyl-pentane, 3-methyl-pentane, 2,2-dimethylbutane, and 2,3-dimethylbutane) was studied in a jet-stirred reactor (JSR) at atmospheric pressure under stoichiometric conditions between 550 and 1000 K. The evolution of reactant and product mole fraction profiles were recorded as a function of the temperature using two analytical methods: gas chromatography and synchrotron vacuum ultraviolet photoionization mass spectrometry (SVUV-PIMS). Experimental data obtained with both methods were in good agreement for the five fuels. These data were used to compare the reactivity and the nature of the reaction products and their distribution. At low temperature (below 800 K), n-hexane was the most reactive isomer. The two methyl-pentane isomers have about the same reactivity, which was lower than that of n-hexane. 2,2-Dimethylbutane was less reactive than the two methyl-pentane isomers, and 2,3-dimethylbutane was the least reactive isomer. These observations are in good agreement with research octane numbers given in the literature. Cyclic ethers with rings including 3, 4, 5, and 6 atoms have been identified and quantified for the five fuels. While the cyclic ether distribution was notably more detailed than in other literature of JSR studies of branched alkane oxidation, some oxiranes were missing among the cyclic ethers expected from methyl-pentanes. Using SVUV-PIMS, the formation of C-2-C-3 monocarboxylic acids, ketohydroperoxides, and species with two carbonyl groups have also been observed, supporting their possible formation from branched reactants. This is in line with what was previously experimentally demonstrated from linear fuels. Possible structures and ways of decomposition of the most probable ketohydroperoxides were discussed. Above 800 K, all five isomers have about the same reactivity, with a larger formation from branched alkanes of some unsaturated species, such as allene and propyne, which are known to be soot precursors.

  DOI：

  10.1021/jp503772h

文献信息

• Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：US20160095858A1

  公开（公告）日：2016-04-07

  The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

  本发明涉及一种具有以下化学式I的化合物： 或其药用可接受的盐，其中R 1 ，R 2 ，R 3 ，W，X，Y，Z，n，o，p和q在此处定义，用于治疗CFTR介导的疾病，如囊性纤维化。本发明还涉及药物组合物、治疗方法和相关工具包。
• Pyrazole glucokinase activators
  申请人：Berthel Steven Joseph

  公开号：US20080021032A1

  公开（公告）日：2008-01-24

  Disclosed herein are pyrazole glucokinase activators of the formula (I) useful for the treatment of metabolic diseases and disorders, preferably diabetes mellitus.

  本文披露了一种式(I)的吡唑葡萄糖激酶激活剂，用于治疗代谢性疾病和紊乱，最好是糖尿病。
• ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF
  申请人：Samumed, LLC

  公开号：US20170313681A1

  公开（公告）日：2017-11-02

  Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

  揭示了用于治疗各种疾病和病理的异喹啉化合物。更具体地，本公开涉及使用异喹啉化合物或其类似物治疗由Wnt途径信号激活所特征的疾病（例如癌症、异常细胞增殖、血管生成、阿尔茨海默病、肺部疾病、炎症、自身免疫疾病和骨关节炎），以及通过Wnt途径信号介导的细胞事件的调节，以及与DYRK1A过表达相关的神经状况/疾病/疾病。
• [EN] ISOXAZOLIDINE DERIVED INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE 1 (RIPK 1)<br/>[FR] INHIBITEURS DÉRIVÉS D'ISOXAZOLIDINE DE PROTÉINE KINASE 1 INTERAGISSANT AVEC UN RÉCEPTEUR (RIPK 1)
  申请人：DENALI THERAPEUTICS INC

  公开号：WO2017096301A1

  公开（公告）日：2017-06-08

  The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.

  本公开涉及一般用于预防或阻止细胞死亡和/或炎症的方法和组合物。
• PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE
  申请人：Castanedo Georgette

  公开号：US20110207713A1

  公开（公告）日：2011-08-25

  Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  Formula I 化合物，包括立体异构体、几何异构体、互变异构体、代谢物及其药学上可接受的盐，对抑制 PI3K 的δ异构体以及治疗由脂质激酶介导的疾病，如炎症、免疫性疾病和癌症，具有用途。公开了利用 Formula I 化合物在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗此类疾病，或相关病理条件的方法。